Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Dennis Purcell has served as the senior managing director of Aisling Capital since February 2000, and is responsible for the management of the partnership. Prior to joining Aisling Capital, Purcell served as managing director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) and was a member of the operating committee. Prior to joining H&Q, Purcell was a managing director in the healthcare group at Paine Webber Inc. Purcell has served on the boards of directors of numerous public and private companies. He is a member of the board of the Life Sciences Foundation, L.E.K. Consulting, a special advisor to Poliwogg Holdings Inc. and an external advisory board member of the NYU Office of Therapeutics Alliances. He has previously served on the boards of the Biotechnology Industry Organization, the New York Biotechnology Association, the Irvington Institute, and was a member of the Advisory Council of Harvard Medical School. In addition to being a regular speaker and commentator on the industry, Purcell has authored articles in Nature Biotechnology, Xconomy, and the Journal of Biolaw and Business. Purcell has been honored in the "Biotech Hall of Fame" by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, and cited as one of the top 100 contributors to the biotechnology industry. Purcell received his master's degree in business administration from Harvard University, and his bachelor's degree in accounting from the University of Delaware.
Promising Biotechs Target New Ways to Kill Bad Bugs: Venture Capitalist Dennis Purcell (3/18/14) Dennis Purcell, senior managing partner of Aisling Capital, has seen the biotechnology industry morph from exciting science project to a full-blown, multibillion-dollar industry producing blockbuster products that routinely save lives. Now a new crisis is looming, as drug-resistant bacteria evolve, proliferate and wreak havoc. With this dire need driving interest, Purcell believes a change of focus, from oncology and orphan drug indications to anti-infectives, will develop in 2014 and beyond. In this interview with The Life Sciences Report, Purcell shares ideas that could offer a definitive cure for your portfolio.